UBS Maintains Buy on Dentsply Sirona, Lowers Price Target to $13

Benzinga · 2d ago
UBS analyst Kevin Caliendo maintains Dentsply Sirona (NASDAQ:XRAY) with a Buy and lowers the price target from $17 to $13.